90 related articles for article (PubMed ID: 32081558)
1. ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma.
Kim H; Choi JY; Rah YC; Ahn JC; Kim H; Jeong WJ; Ahn SH
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Apr; 129(4):377-387. PubMed ID: 32081558
[TBL] [Abstract][Full Text] [Related]
2. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
3. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.
Silva SD; Cunha IW; Younes RN; Soares FA; Kowalski LP; Graner E
Oral Dis; 2010 Nov; 16(8):774-80. PubMed ID: 20604875
[TBL] [Abstract][Full Text] [Related]
4. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
5. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
6. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
Duvvuri U; George J; Kim S; Alvarado D; Neumeister VM; Chenna A; Gedrich R; Hawthorne T; LaVallee T; Grandis JR; Bauman JE
Clin Cancer Res; 2019 Oct; 25(19):5752-5758. PubMed ID: 31308059
[TBL] [Abstract][Full Text] [Related]
7. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.
Chi LH; Chang WM; Chang YC; Chan YC; Tai CC; Leung KW; Chen CL; Wu AT; Lai TC; Li YJ; Hsiao M
Sci Rep; 2017 Aug; 7(1):9031. PubMed ID: 28831179
[TBL] [Abstract][Full Text] [Related]
8. Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.
Zhang K; Jones L; Lim S; Maher CA; Adkins D; Lewis J; Kimple RJ; Fertig EJ; Chung CH; Van Tine BA; Ellis MJ; Herrlich A; Michel LS
Oncotarget; 2014 Oct; 5(19):9281-94. PubMed ID: 25238142
[TBL] [Abstract][Full Text] [Related]
9. Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.
Birkeland AC; Yanik M; Tillman BN; Scott MV; Foltin SK; Mann JE; Michmerhuizen NL; Ludwig ML; Sandelski MM; Komarck CM; Carey TE; Prince ME; Bradford CR; McHugh JB; Spector ME; Brenner JC
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):559-67. PubMed ID: 27077364
[TBL] [Abstract][Full Text] [Related]
10. An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma.
Citron F; Armenia J; Franchin G; Polesel J; Talamini R; D'Andrea S; Sulfaro S; Croce CM; Klement W; Otasek D; Pastrello C; Tokar T; Jurisica I; French D; Bomben R; Vaccher E; Serraino D; Belletti B; Vecchione A; Barzan L; Baldassarre G
Clin Cancer Res; 2017 Jul; 23(14):3769-3780. PubMed ID: 28174235
[No Abstract] [Full Text] [Related]
11. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
[TBL] [Abstract][Full Text] [Related]
12. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.
Redlich N; Robinson AM; Nickel KP; Stein AP; Wheeler DL; Adkins DR; Uppaluri R; Kimple RJ; Van Tine BA; Michel LS
Cell Death Dis; 2018 Jan; 9(1):5. PubMed ID: 29305574
[TBL] [Abstract][Full Text] [Related]
13. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
14. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
15. Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis.
Chang YC; Chi LH; Chang WM; Su CY; Lin YF; Chen CL; Chen MH; Chang PM; Wu AT; Hsiao M
J Hematol Oncol; 2017 Jan; 10(1):11. PubMed ID: 28061796
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
17. Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression.
Alterio D; Marvaso G; Maffini F; Gandini S; Chiocca S; Ferrari A; Preda L; Rocca MC; Lepanto D; Fodor C; Volpe S; Dicuonzo S; Laudati A; Giugliano G; Ansarin M; Jereczek-Fossa BA
Med Oncol; 2017 Jun; 34(6):107. PubMed ID: 28452036
[TBL] [Abstract][Full Text] [Related]
18. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
19. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
[TBL] [Abstract][Full Text] [Related]
20. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
